Screener / SEC EDGAR /CIK 0001739104 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Elanco Animal Health Inc ELAN

Compare with peers Embed
What it said it expected, against what it reported

7 targets with a reported result

Releases of the last 3 years
Above the range 4 above the last range given
Within the range 3 of 7 range targets
Below the range 0 below the last range given

The numbers ELAN said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Free cash flow (company-defined)
Fiscal 2028
Given at least $1.00B release Feb 24, 2026
– No standard number
The company's words
Expecting free cash flow of at least $1 billion over the period from 2026 through 2028, and further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x release Feb 24, 2026
EBITDA (company-defined)
Fiscal 2026
Given $955.00M to $985.00M release Feb 24, 2026
Raised $975.00M to $1.00B release May 6, 2026
Raised $1.01B to $1.03B release Aug 5, 2026
Raised $1.05B to $1.06B release Nov 6, 2026
– No standard number
The company's words
Full Year 2026 Guidance: … Adjusted EBITDA of $955 million to $985 million, an increase of 8% at midpoint release Feb 24, 2026
Full Year 2026 Guidance: … Raising Adjusted EBITDA to $975 million to $1,005 million, a year-over-year increase of 10% at midpoint release May 6, 2026
Full Year 2026 Guidance: … Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint release Aug 5, 2026
Full Year 2026 Guidance: … Raising Adjusted EBITDA guidance to $1.05 billion to $1.065 billion, a year- over-year increase of 17% at midpoint release Nov 6, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $1.00 to $1.06 release Feb 24, 2026
Raised $1.03 to $1.09 release May 6, 2026
Raised $1.10 to $1.16 release Aug 5, 2026
Raised $1.17 to $1.20 release Nov 6, 2026
– No standard number
The company's words
Full Year 2026 Guidance: … Adjusted EPS of $1.00 to $1.06, an increase of 10% at midpoint release Feb 24, 2026
Full Year 2026 Guidance: … Raising Adjusted EPS of $1.03 to $1.09, a year-over-year increase of 13% at midpoint release May 6, 2026
Full Year 2026 Guidance: … Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint release Aug 5, 2026
Full Year 2026 Guidance: … Raising Adjusted EPS guidance to $1.17 to $1.20, a year-over-year increase of 26% at midpoint release Nov 6, 2026
Revenue
Fiscal 2026
Given $4.95B to $5.02B release Feb 24, 2026
Raised $5.01B to $5.08B release May 6, 2026
Raised $5.09B to $5.14B release Aug 5, 2026
Raised $5.16B to $5.18B release Nov 6, 2026
– Not reported yet
The company's words
Full Year 2026 Guidance: … Revenue of $4,950 million to $5,020 million, or 4% to 6% organic constant currency growth release Feb 24, 2026
Full Year 2026 Guidance: … Raising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growth release May 6, 2026
Full Year 2026 Guidance: … Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth release Aug 5, 2026
Full Year 2026 Guidance: … Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8% organic constant currency growth release Nov 6, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $830.00M to $870.00M release Feb 25, 2025
Lowered $200.00M to $220.00M release May 7, 2025
Lowered $160.00M to $180.00M release Aug 7, 2025
Raised $168.00M to $188.00M release Nov 5, 2025
– No standard number
The company's words
2025 Full Year Guidance (dollars in millions, except per share amounts) … Adjusted EBITDA $830 to $870 release Feb 25, 2025
2025 Second Quarter Guidance (dollars in millions, except per share amounts) … Adjusted EBITDA $200 to $220 release May 7, 2025
2025 Third Quarter Guidance (dollars in millions, except per share amounts) … Adjusted EBITDA $160 to $180 release Aug 7, 2025
2025 Fourth Quarter Guidance (dollars in millions, except per share amounts) … Adjusted EBITDA $168 to $188 release Nov 5, 2025
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $0.80 to $0.86 release Feb 25, 2025
Kept $0.80 to $0.86 release May 7, 2025
Kept $0.80 to $0.86 release Aug 7, 2025
Raised $0.85 to $0.91 release Nov 5, 2025
– No standard number
The company's words
2025 Full Year Guidance (dollars in millions, except per share amounts) … Adjusted Earnings per Share $0.80 to $0.86 release Feb 25, 2025
2025 Full Year (dollars in February May millions, except Guidance Guidance per share amounts) … Adjusted Earnings per Share $0.80 to $0.86 release May 7, 2025
2025 Full Year (dollars in May August millions, except Guidance Guidance per share amounts) … Adjusted Earnings per Share $0.80 to $0.86 release Aug 7, 2025
2025 Full Year (dollars in August November millions, except Guidance Guidance per share amounts) … Adjusted Earnings per Share $0.85 to $0.91 release Nov 5, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $960.00M to $1.01B release Feb 26, 2024
Lowered $900.00M to $940.00M release Aug 8, 2024
Lowered $900.00M to $930.00M release Nov 7, 2024
– No standard number
The company's words
2024 Full Year Guidance (dollars in millions, except per share amounts) … Adjusted EBITDA $960 to $1,010 release Feb 26, 2024
Updating full year 2024 financial guidance to reflect aqua divestiture and expected contribution from Bovaer and Zenrelia: … Adjusted EBITDA of $900 to $940 million; release Aug 8, 2024
Tightening full year 2024 financial guidance to reflect current assumptions: … Adjusted EBITDA of $900 to $930 million; release Nov 7, 2024
Net income
Fiscal 2024 (ended Dec 31, 2024)
Given $314.00M to $352.00M release Aug 8, 2024
Lowered $286.00M to $317.00M release Nov 7, 2024
$338.00M
10-K filed 2025-02-25
Above the range
The company's words
Updating full year 2024 financial guidance to reflect aqua divestiture and expected contribution from Bovaer and Zenrelia: … Reported Net Income of $314 to $352 million; release Aug 8, 2024
Tightening full year 2024 financial guidance to reflect current assumptions: … Reported Net Income of $286 to $317 million; release Nov 7, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $0.87 to $0.95 release Feb 26, 2024
Raised $0.88 to $0.96 release May 8, 2024
Kept $0.88 to $0.96 release Aug 8, 2024
Narrowed $0.89 to $0.95 release Nov 7, 2024
– No standard number
The company's words
Full Year 2024 Guidance: … Reported EPS of $(0.12) to $(0.03), Adjusted EPS of $0.87 to $0.95 release Feb 26, 2024
Full Year 2024 Guidance … Adjusted earnings per share(2) $0.88 to $0.96 release May 8, 2024
Updating full year 2024 financial guidance to reflect aqua divestiture and expected contribution from Bovaer and Zenrelia: … Adjusted EPS of $0.88 to $0.96 release Aug 8, 2024
Tightening full year 2024 financial guidance to reflect current assumptions: … Adjusted EPS of $0.89 to $0.95 release Nov 7, 2024
Diluted EPS
Fiscal 2024 (ended Dec 31, 2024)
Given $0.63 to $0.71 release Aug 8, 2024
Lowered $0.58 to $0.64 release Nov 7, 2024
$0.68
10-K filed 2025-02-25
Above the range
The company's words
Updating full year 2024 financial guidance to reflect aqua divestiture and expected contribution from Bovaer and Zenrelia: … Reported EPS of $0.63 to $0.71 release Aug 8, 2024
Tightening full year 2024 financial guidance to reflect current assumptions: … Reported EPS of $0.58 to $0.64 release Nov 7, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $4.45B to $4.54B release Feb 26, 2024
Lowered $4.41B to $4.46B release Aug 8, 2024
Narrowed $4.42B to $4.45B release Nov 7, 2024
$4.44B
10-K filed 2025-02-25
Within the range
The company's words
Full Year 2024 Guidance: … Revenue of $4,450 to $4,540 million release Feb 26, 2024
Updating full year 2024 financial guidance to reflect aqua divestiture and expected contribution from Bovaer and Zenrelia: … Revenue of $4,410 to $4,460 million, with organic constant currency growth raised to 3% to 4% release Aug 8, 2024
Tightening full year 2024 financial guidance to reflect current assumptions: … Revenue of $4,420 to $4,450 million, with organic constant currency growth of 3% release Nov 7, 2024
Revenue (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $420.00M to $450.00M release Nov 7, 2024
– No standard number
The company's words
The tightened 2024 revenue guidance continues to reflect 3% organic constant currency growth inclusive of higher innovation sales contribution, now expected between $420 million to $450 million for the full year, offset by lowered expectations for U.S. Pet Health parasiticides. release Nov 7, 2024
Revenue
Q4 of fiscal 2024
Given $1.00B to $1.03B release Nov 7, 2024
$1.02B
10-K filed 2025-02-25
Within the range
The company's words
For the fourth quarter of 2024, the company anticipates revenue between $1.00 billion and $1.03 billion, with a headwind of approximately $5 million from the unfavorable impact of foreign exchange rates compared to the prior year. release Nov 7, 2024
Revenue
Q3 of fiscal 2024
Given $1.02B to $1.05B release Aug 8, 2024
$1.03B
10-Q filed 2024-11-07
Within the range
The company's words
5 For the third quarter of 2024, the company anticipates revenue between $1.02 billion and $1.05 billion, with a headwind of approximately $20 million from the unfavorable impact of foreign exchange rates compared to the prior year. release Aug 8, 2024
EBITDA (company-defined)
Q2 of fiscal 2024
Given $240.00M to $260.00M release May 8, 2024
– No standard number
The company's words
2024SecondQuarter Guidance (dollars in millions, except per share amounts) … Adjusted EBITDA $240 to $260 release May 8, 2024
Diluted EPS (company-defined)
Q2 of fiscal 2024
Given $0.23 to $0.26 release May 8, 2024
– No standard number
The company's words
2024SecondQuarter Guidance (dollars in millions, except per share amounts) … Adjusted Earnings per Share $0.23 to $0.26 release May 8, 2024
Revenue
Q2 of fiscal 2024
Given $1.15B to $1.17B release May 8, 2024
$1.18B
10-Q filed 2024-08-08
Above the range
The company's words
2024SecondQuarter Guidance (dollars in millions, except per share amounts) … Revenue $1,145 to $1,170 release May 8, 2024
Revenue
Q1 of fiscal 2024
Given $1.16B to $1.19B release Feb 26, 2024
$1.21B
10-Q filed 2024-05-08
Above the range
The company's words
In the first quarter, the company expects revenue between $1,160 million and $1,185 million, with a headwind of approximately $5 million from the impact of foreign exchange rates compared to prior year. release Feb 26, 2024
2 targets far from the company's reported total, so not compared (usually a target for one product, segment or definition)

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-26), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ELAN/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.